Intraperitoneal Chemotherapy Ups Ovarian Cancer Outcomes

This article originally appeared here.
Share this content:
Intraperitoneal Chemotherapy Ups Ovarian Cancer Outcomes
Intraperitoneal Chemotherapy Ups Ovarian Cancer Outcomes

WEDNESDAY, Aug. 5, 2015 (HealthDay News) -- Intraperitoneal chemotherapy significantly improves survival among women with advanced ovarian cancer; however, fewer than half of eligible U.S. patients are receiving it, according to research published online Aug. 3 in the Journal of Clinical Oncology.

The investigators studied whether a combination of intraperitoneal (IP) and intravenous (IV) chemotherapy was as effective in clinical practice as in a clinical trial involving women who'd had surgery for stage III ovarian cancer. The researchers examined the medical records of 823 women who were treated for stage III ovarian cancer between 2003 and 2012, and were eligible for IP/IV combination therapy.

The team found that 81 percent of women who received the dual therapy were alive three years after treatment, compared with 71 percent of those who received IV chemotherapy alone. However, only 41 percent of the patients who were deemed to be suitable candidates actually received the dual therapy, the team reported. The investigators also found that the side effects of the dual therapy were less severe than those reported in the clinical trial.

"This is the first study to show that IP/IV chemotherapy improves survival in the real world, outside of a clinical trial," first author Alexi Wright, M.D., of the Dana-Farber Cancer Institute in Boston, said in an institute news release. "Unfortunately, fewer than half of women who qualify for IP/IV chemotherapy received the treatment. This suggests that increasing access to IP/IV chemotherapy may improve ovarian cancer patients' survival."

Several authors disclosed financial ties to pharmaceutical, biotechnology, and medical device companies.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ancient Gene Protects Elephants From Cancer

Ancient Gene Protects Elephants From Cancer

The LIF6 gene destroys cells with damaged DNA

Reasons for Undergoing Cosmetic Procedures Explored

Reasons for Undergoing Cosmetic Procedures Explored

Psychological and emotional motivations more likely in patients wanting acne scar tx, tattoo removal

DNR Orders Linked to Increased Mortality in Older Adults

DNR Orders Linked to Increased Mortality in Older ...

Early versus late DNR tied to shorter median length of stay in hospitalized adults aged 65 years and older

is free, fast, and customized just for you!




Already a member?

Sign In Now »